Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab

被引：27

作者：

Fink, A. M. ^{[1
,2
,15
,16
]}

Bottcher, S. ^{[3
,15
,16
]}

Ritgen, M. ^{[3
]}

Fischer, K. ^{[1
,2
]}

Pflug, N. ^{[1
,2
]}

Eichhorst, B. ^{[1
,2
]}

Wendtner, C-M ^{[1
,2
]}

Winkler, D. ^{[4
]}

Buhler, A. ^{[4
]}

Zenz, T. ^{[4
,5
,6
,7
]}

Staib, P. ^{[8
]}

Mayer, J. ^{[9
,10
,11
]}

Hensel, M. ^{[5
,6
,7
]}

Hopfinger, G. ^{[12
]}

Wenger, M. ^{[13
]}

Fingerle-Rowson, G. ^{[1
,2
]}

Dohner, H. ^{[4
]}

Kneba, M. ^{[3
]}

Stilgenbauer, S. ^{[4
]}

Busch, R. ^{[14
]}

Hallek, M. ^{[1
,2
]}

机构：

[1] Dept Internal Med 1, Cologne, Germany

[2] Ctr Integrated Oncol Cologne Bonn, Cologne, Germany

[3] Univ Hosp Schleswig Holstein, Dept Med 2, Kiel, Germany

[4] Klinikum Munchen Schwabing, Munich, Germany

[5] Univ Ulm, Dept Internal Med 3, Ulm, Germany

[6] Natl Ctr Tumor Dis NCT, Dept Translat Oncol, Heidelberg, Germany

[7] German Canc Res Ctr, Heidelberg, Germany

[8] Heidelberg Univ, Dept Med 5, Heidelberg, Germany

[9] St Antonius Hosp Eschweiler, Klin Hamatol & Onkol, Eschweiler, Germany

[10] Univ Hosp Brno, Dept Internal Med Hematol & Oncol, Brno, Czech Republic

[11] Masaryk Univ, CEITEC, Brno, Czech Republic

[12] Mannheimer Onkol Praxis, Mannheim, Germany

[13] Hanusch Hosp Vienna, Dept Med 3, Vienna, Austria

[14] Paracelsus Med Univ, Dept Med 3, Salzburg, Austria

[15] F Hoffmann Roche Ltd, Pharmaceut Div, Basel, Switzerland

[16] Tech Univ, Inst Med Stat & Epidemiol, Munich, Germany

来源：

LEUKEMIA | 2013年 / 27卷 / 09期

关键词：

CHRONIC LYMPHOCYTIC-LEUKEMIA; SURVIVAL; QUANTIFICATION; PROGRESSION;

D O I：

10.1038/leu.2013.190

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1949 / +

页数：5

共 50 条

[21] Immunochemotherapy with rituximab in combination with fludarabine and epirubicine as first-line treatment in patients with chronic lymphocytic leukemia
Chow, K. U.
Kim-Wanner, S.
Hermann, S.
Wunderle, L.
Cordes, H. J.
Bergmann, L., Sr.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[22] Fludarabine, Cyclophosphamide and Rituximab (FCR) As First Line Treatment in Patients with Chronic Lymphocytic Leukemia (CLL): A Long-Term Analysis of the German CLL Study Group (GCLLSG) Registry
Kutsch, Nadine
Fink, Anna Maria
Federhen, Anno
Giza, Adam
Robrecht, Sandra
Stumpf, Janina
Stoltefuss, Andrea
Vehling-Kaiser, Ursula
Koenigsmann, Michael
Tausch, Eugen
Schneider, Christof
Stilgenbauer, Stephan
Illmer, Thomas
Schlag, Rudolf
Doerfel, Steffen
Gaska, Tobias
Kiehl, Michael G.
Fischer, Kirsten
Eichhorst, Barbara
Hallek, Michael
BLOOD, 2022, 140 : 9879 - 9881
[23] Combined therapy of rituximab, fludarabine and cyclophosphamide (R-FC) as a first-line treatment is safe and efficacious for younger patients with B-cell chronic lymphocytic leukemia (B-CLL).
Ranze, OP
Arland, M
Hoffkes, HG
BLOOD, 2003, 102 (11) : 355B - 356B
[24] Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia
Mueller, Dirk
Fischer, Kirsten
Kaiser, Peter
Eichhorst, Barbara
Walshe, Ronald
Reiser, Marcel
Kellermann, Lenka
Borsi, Lisa
Civello, Daniele
Mensch, Alexander
Bahlo, Jasmin
Hallek, Michael
Stock, Stephanie
Fingerle-Rowson, Guenter
LEUKEMIA & LYMPHOMA, 2016, 57 (05) : 1130 - 1139
[25] Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) for First-Line Treatment of Patients With CLL With Mutated IGHV and Without TP53 Aberration
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (01) : 6 - 8
[26] Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia
Abrisqueta, Pau
Villamor, Neus
Jose Terol, Maria
Gonzalez-Barca, Eva
Gonzalez, Marcos
Ferra, Christelle
Abella, Eugenia
Delgado, Julio
Garcia-Marco, Jose A.
Gonzalez, Yolanda
Carbonell, Felix
Ferrer, Secundino
Monzo, Encarna
Jarque, Isidro
Muntanola, Ana
Constants, Mireia
Escoda, Lourdes
Calvo, Xavier
Bobillo, Sabela
Bruno Montoro, Jose
Montserrat, Emili
Bosch, Francesc
BLOOD, 2013, 122 (24) : 3951 - 3959
[27] Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group
Cramer, Paula
Fink, Anna-Maria
Busch, Raymonde
Eichhorst, Barbara
Wendtner, Clemens-Martin
Pflug, Natali
Langerbeins, Petra
Bahlo, Jasmin
Goede, Valentin
Schubert, Friederike
Doehner, Hartmut
Stilgenbauer, Stephan
Dreger, Peter
Kneba, Michael
Boettcher, Sebastian
Mayer, Jiri
Hallek, Michael
Fischer, Kirsten
LEUKEMIA & LYMPHOMA, 2013, 54 (08) : 1821 - 1822
[28] Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) for First-Line Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations
Jain, Nitin
Thompson, Philip A.
Burger, Jan A.
Borthakur, Gautam
Bose, Prithviraj
Estrov, Zeev
Ferrajoli, Alessandra
Takahashi, Koichi
Garg, Naveen
Wang, Xuemei
Gandhi, Varsha
Plunkett, William
Kanagal-Shamanna, Rashmi
Patel, Keyur
Lopez, Wanda
Kantarjian, Hagop M.
O'Brien, Susan M.
Keating, Michael J.
Wierda, William G.
BLOOD, 2017, 130
[29] Toxicity Is Not Associated with Age or Comorbidity Score in a Randomised Study of Oral Fludarabine and Cyclophosphamide and IV Rituximab (FCR) As First-Line Therapy of Fit, Elderly Patients with Chronic Lymphocytic Leukemia (CLL)
Mulligan, Stephen P.
Gill, Devinder
Turner, Paul
Renwick, William E. P.
Latimer, Maya
Mackinlay, Naomi
Berkahn, Leanne
Simpson, David R.
Campbell, Philip
Forsyth, Cecily J.
Cull, Gavin
Harrup, Rosemary
Sulda, Melanie
Best, Giles
Bressel, Mathias
Di Iulio, Juliana
Kuss, Bryone J.
BLOOD, 2014, 124 (21)
[30] Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia
Eichhorst, BF
Busch, R
Hopfinger, G
Pasold, R
Hensel, M
Steinbrecher, C
Siehl, S
Jäger, U
Bergmann, M
Stilgenbauer, S
Schweighofer, C
Wendtner, CM
Döhner, H
Brittinger, G
Emmerich, B
Hallek, M
BLOOD, 2006, 107 (03) : 885 - 891

← 1 2 3 4 5 →